TY - JOUR
T1 - Marginal ulceration after Roux-en-Y gastric bypass surgery
T2 - Characteristics, risk factors, treatment, and outcomes
AU - Azagury, D. E.
AU - Abu Dayyeh, B. K.
AU - Greenwalt, I. T.
AU - Thompson, C. C.
PY - 2011
Y1 - 2011
N2 - Background and study aims: Marginal ulcers are one of the most common complications after gastric bypass. Reported incidence varies widely (0.616%) and pathogenesis is unclear. The aim of the present study was to describe characteristics, risk factors, management, and outcomes of endoscopically documented ulcers. Patients and methods: Data from all patients diagnosed with marginal ulcers at endoscopy between 2003 and 2010 were retrospectively reviewed. Results: A total of 103patients with marginal ulcers presented with pain (63%) and/or bleeding (24%), a median of 22 months after surgery. Ulcers were located on the anastomosis (50%) or the jejunum (40%); sutures were visible in 35%, and gastrogastric fistulae in 8%. The mean pouch length was 5.6cm. Diabetes (odds ratio [OR] 2.5; P=0.03), smoking (OR 2.5; P=0.02), and gastric pouch length (OR 1.2; P=0.02) were significantly associated with marginal ulcer formation on univariate analysis; diabetes was significantly associated on multivariate analysis (OR 5.6; P=0.003). The risk of developing a marginal ulcer decreased with time (OR 0.8; P<0.01) and was not associated with the use of nonsteroidal anti-inflammatory drugs. At first endoscopic follow-up, 67% of ulcers had healed. Recurrence occurred in four patients and nine patients required surgical revision. Conclusions: The vast majority of marginal ulcers had a favorable outcome after medical treatment. However, 9% of patients eventually required surgical revision. Therefore, endoscopic follow-up is essential. Diabetes, smoking, and long gastric pouches were significant risk factors for marginal ulcer formation, suggesting increased acid exposure and mucosal ischemia are both involved in marginal ulcer pathogenesis. Management of these factors may prove effective in managing marginal ulcers, and tailoring postoperative proton pump inhibitor therapy to patients with multiple risk factors could be effective.
AB - Background and study aims: Marginal ulcers are one of the most common complications after gastric bypass. Reported incidence varies widely (0.616%) and pathogenesis is unclear. The aim of the present study was to describe characteristics, risk factors, management, and outcomes of endoscopically documented ulcers. Patients and methods: Data from all patients diagnosed with marginal ulcers at endoscopy between 2003 and 2010 were retrospectively reviewed. Results: A total of 103patients with marginal ulcers presented with pain (63%) and/or bleeding (24%), a median of 22 months after surgery. Ulcers were located on the anastomosis (50%) or the jejunum (40%); sutures were visible in 35%, and gastrogastric fistulae in 8%. The mean pouch length was 5.6cm. Diabetes (odds ratio [OR] 2.5; P=0.03), smoking (OR 2.5; P=0.02), and gastric pouch length (OR 1.2; P=0.02) were significantly associated with marginal ulcer formation on univariate analysis; diabetes was significantly associated on multivariate analysis (OR 5.6; P=0.003). The risk of developing a marginal ulcer decreased with time (OR 0.8; P<0.01) and was not associated with the use of nonsteroidal anti-inflammatory drugs. At first endoscopic follow-up, 67% of ulcers had healed. Recurrence occurred in four patients and nine patients required surgical revision. Conclusions: The vast majority of marginal ulcers had a favorable outcome after medical treatment. However, 9% of patients eventually required surgical revision. Therefore, endoscopic follow-up is essential. Diabetes, smoking, and long gastric pouches were significant risk factors for marginal ulcer formation, suggesting increased acid exposure and mucosal ischemia are both involved in marginal ulcer pathogenesis. Management of these factors may prove effective in managing marginal ulcers, and tailoring postoperative proton pump inhibitor therapy to patients with multiple risk factors could be effective.
UR - http://www.scopus.com/inward/record.url?scp=80555131026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80555131026&partnerID=8YFLogxK
U2 - 10.1055/s-0030-1256951
DO - 10.1055/s-0030-1256951
M3 - Article
C2 - 21997722
AN - SCOPUS:80555131026
SN - 0013-726X
VL - 43
SP - 950
EP - 954
JO - Endoscopy
JF - Endoscopy
IS - 11
ER -